Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Canada can override patents to combat drug, equipment shortages during the pandemic

Laura Eggertson
CMAJ April 20, 2020 192 (16) E438-E439; DOI: https://doi.org/10.1503/cmaj.1095862
Laura Eggertson
Wolfville, N.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

The federal government now has additional powers to override patents for drugs, vaccines and medical equipment as needed to secure critical supplies during the COVID-19 pandemic.

Amendments to the Patent Act under Canada’s COVID-19 Emergency Response Act make it possible for the federal government – or anyone it designates – to make, use and sell patented inventions “to the extent necessary to respond to a public health emergency.”

Effectively, the act enables Ottawa to combat price gouging or shortages of any needed product, from vaccines to ventilators, by licensing companies to make generic copies of brand-name products without having to negotiate with patent holders. These compulsory licences would last only a year, and patent holders would receive “adequate” compensation, to be determined after the fact.

According to Innovation, Science and Economic Development Canada, the new rules are intended to ensure that patents are not a barrier to securing supplies during the pandemic.

Health Canada will also speed up its regulatory process for any vaccine or therapeutic product intended to treat COVID-19, including reviews of drug submissions and clinical trial applications.

“This piece of legislation is a good response to the emergency that we’re facing,” said Dr. Joel Lexchin, professor emeritus of Health Policy and Management at York University in Toronto. He noted that some countries like Australia are already experiencing shortages of critical medicines due to panic buying.

Canada’s deputy health minister recently warned that disruptions in global supply chains during the pandemic will likely cause drug shortages here too.

Figure

Provisions of recent emergency legislation will make it easier for Canada to issue compulsory licences for medical products.

Image courtesy of iStock.com/JurgaR

“The Patent Act should not stand in the way of emergencies of this nature,” said Philip Kerr, an Ottawa patent and trade lawyer. Previously, Canada’s patent commissioner had discretion over whether to authorize the government to use patented products during emergencies, and the government had to prove it had tried to work out a deal with the patent holder first. There are no such conditions under the new legislation.

The new rules also enable Ottawa to specify third parties to make, use and sell patented products. Kerr said this change should embolden smaller companies to apply to build ventilators or other critical medical devices during the pandemic.

Brand-name pharmaceutical companies have opposed previous Canadian efforts to authorize third parties to make and sell patented products, also known as compulsory licensing.

In this case, the industry’s main concern is that “the government does not have to check with the original manufacturer to see if they can supply a product,” said Sarah Dion-Marquis of Innovative Medicines Canada, the national association for brand-name drug companies. “That said, the time limitation in the amendment clearly recognizes that this is an extraordinary measure intended only for potential use during the current public health crisis.”

Jim Keon, president of the Canadian Generic Pharmaceutical Association, welcomed the new measures as “prudent and reasonable.” In a statement, Keon noted that international trade agreements to which Canada is party uphold the ability of countries to issue compulsory licences for medicines and other urgently needed items to respond to a health crisis.

According to Lexchin, the biggest challenge generic companies may face if they are asked to produce patented medicines is a potential shortage of active ingredients from major producers like India and China.

India, home to the world’s largest drug manufacturers, has banned the export of 26 pharmaceutical ingredients and products because of shortages in their supply. The export ban includes the antimalarial drug hydroxychloroquine, which is being studied in clinical trials as a potential treatment for COVID-19.

Generic drug companies are closely monitoring their orders and inventories, said Jeff Connell, vice-president of corporate affairs at the Canadian Generic Pharmaceutical Association. He did not comment directly on any shortages of active ingredients.

“Our industry is also working with our international partners to mitigate the potential for shortages in Canada,” Connell said.

Footnotes

  • Posted on cmajnews.com on April 2, 2020

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (16)
CMAJ
Vol. 192, Issue 16
20 Apr 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Canada can override patents to combat drug, equipment shortages during the pandemic
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Canada can override patents to combat drug, equipment shortages during the pandemic
Laura Eggertson
CMAJ Apr 2020, 192 (16) E438-E439; DOI: 10.1503/cmaj.1095862

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Canada can override patents to combat drug, equipment shortages during the pandemic
Laura Eggertson
CMAJ Apr 2020, 192 (16) E438-E439; DOI: 10.1503/cmaj.1095862
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Canadian government
    • Drug regulation
    • Health policy
    • Infectious diseases

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire